Presence of HER-2 Protein a Plus in Breast Cancer Chemotherapy

Thursday, October 11th, 2007
This post was written by Melanie Matthews

Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects. The multicenter study, led by University of Michigan Comprehensive Cancer Center researchers, found that:

Women whose breast cancer expressed a protein called HER-2 were most likely to benefit from adding the drug Taxol to the chemotherapy regimen, while women whose tumors were fueled by estrogen but did not express HER-2 did not get any benefit from the added Taxol. About 15 percent to 20 percent of breast cancers express HER-2, and as many as three-quarters of breast cancers are so-called estrogen-receptor-positive.

Related Posts:

Comments are closed.